Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

John Mascarenhas, Aaron T. Gerds, Arianna Kee, Jonathan K. Kish, Pranav Abraham, Alexandrina Balanean, Jose Alberto Nadal, Djibril Liassou, Bruce A. Feinberg, Ali McBride, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2021-145573

Published: 2021

Journal Articles

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds

Blood (2021) 138 (Supplement 1): 3059.

https://doi.org/10.1182/blood-2021-145569

Published: 2021

Journal Articles

CAR T Therapy Referral for Diffuse Large B Cell Lymphoma (DLBCL) By U.S. Community Hematology/Oncology (cH/O) Practices: Perceptions and Patterns

David L Porter, Andrew J Klink, Alexandrina Balanean, Lindsay McAllister, Bruce A. Feinberg

Blood (2021) 138 (Supplement 1): 4977.

https://doi.org/10.1182/blood-2021-151807

Published: 2021

Journal Articles

Real-World Adverse Events Associated with Tisagenlecleucel in Acute Lymphoblastic Leukemia and Large B-Cell Lymphoma

Marjorie E Zettler, PhD MPH, Bruce Feinberg, DO, Alexandrina Balanean, Ajeet Gajra, MD MBBS

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142061

Published: 2020